Allstate Corporation’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.9M | Buy |
14,782
+6,094
| +70% | +$1.18M | 0.03% | 379 |
|
|
2025
Q4 | $1.51M | Buy |
8,688
+3,786
| +77% | +$689K | 0.02% | 436 |
|
|
2025
Q3 | $934K | Buy |
+4,902
| New | +$870K | 0.02% | 373 |
|
|
2025
Q2 | – | Sell |
-7,130
| Closed | -$1.21M | – | 273 |
|
|
2025
Q1 | $1.21M | Buy |
7,130
+3,735
| +110% | +$614K | 0.04% | 296 |
|
|
2024
Q4 | $512K | Buy |
+3,395
| New | +$528K | 0.02% | 472 |
|
|
2023
Q1 | – | Sell |
-4,398
| Closed | -$688K | – | 301 |
|
|
2022
Q4 | $688K | Buy |
4,398
+4
| +0.1% | +$575 | 0.02% | 434 |
|
|
2022
Q3 | $539K | Buy |
4,394
+230
| +6% | +$30.3K | 0.02% | 476 |
|
|
2022
Q2 | $554K | Buy |
4,164
+2,555
| +159% | +$348K | 0.02% | 481 |
|
|
2022
Q1 | $220K | Sell |
1,609
-9,570
| -86% | -$1.33M | 0.01% | 575 |
|
|
2021
Q4 | $1.93M | Buy |
11,179
+9,601
| +608% | +$1.46M | 0.04% | 403 |
|
|
2021
Q3 | $229K | Sell |
1,578
-240
| -13% | -$35.1K | 0.01% | 678 |
|
|
2021
Q2 | $240K | Sell |
1,818
-214
| -11% | -$28K | 0.01% | 685 |
|
|
2021
Q1 | $261K | Sell |
2,032
-120
| -6% | -$14.8K | 0.01% | 676 |
|
|
2020
Q4 | $256K | Buy |
2,152
+267
| +14% | +$32.5K | 0.01% | 661 |
|
|
2020
Q3 | $216K | Sell |
1,885
-1,106
| -37% | -$131K | 0.01% | 636 |
|
|
2020
Q2 | $341K | Sell |
2,991
-659
| -18% | -$69.9K | 0.01% | 549 |
|
|
2020
Q1 | $293K | Sell |
3,650
-6,675
| -65% | -$691K | 0.01% | 502 |
|
|
2019
Q4 | $1.1M | Buy |
10,325
+494
| +5% | +$51.5K | 0.02% | 413 |
|
|
2019
Q3 | $1.05M | Buy |
9,831
+6,587
| +203% | +$676K | 0.02% | 381 |
|
|
2019
Q2 | $330K | Sell |
3,244
-42
| -1% | -$4.04K | 0.01% | 447 |
|
|
2019
Q1 | $295K | Buy |
3,286
+31
| +1% | +$2.69K | 0.01% | 380 |
|
|
2018
Q4 | $271K | Buy |
+3,255
| New | +$305K | 0.01% | 364 |
|
|
2017
Q3 | – | Sell |
-26,323
| Closed | -$2.93M | – | 90 |
|
|
2017
Q2 | $2.93M | Buy |
26,323
+7,541
| +40% | +$797K | 0.16% | 60 |
|
|
2017
Q1 | $1.84M | Sell |
18,782
-17,396
| -48% | -$1.66M | 0.11% | 127 |
|
|
2016
Q4 | $3.33M | Buy |
+36,178
| New | +$3.12M | 0.2% | 140 |
|
|
2015
Q4 | – | Sell |
-73,970
| Closed | -$4.55M | – | 182 |
|
|
2015
Q3 | $4.55M | Buy |
73,970
+32,608
| +79% | +$2.28M | 0.47% | 49 |
|
|
2015
Q2 | $3M | Sell |
41,362
-28,209
| -41% | -$2.08M | 0.27% | 82 |
|
|
2015
Q1 | $5.35M | Buy |
69,571
+9,114
| +15% | +$653K | 0.45% | 54 |
|
|
2014
Q4 | $4.05M | Sell |
60,457
-86,395
| -59% | -$5.45M | 0.31% | 119 |
|
|
2014
Q3 | $8.91M | Sell |
146,852
-288,734
| -66% | -$17.8M | 0.41% | 53 |
|
|
2014
Q2 | $25.6M | Buy |
435,586
+77,849
| +22% | +$4.56M | 0.69% | 22 |
|
|
2014
Q1 | $20.7M | Buy |
357,737
+45,731
| +15% | +$2.45M | 0.67% | 21 |
|
|
2013
Q4 | $16.7M | Sell |
312,006
-129,750
| -29% | -$7.7M | 0.62% | 32 |
|
|
2013
Q3 | $27.3M | Buy |
441,756
+112,801
| +34% | +$6.75M | 1.06% | 15 |
|
|
2013
Q2 | $19.9M | Buy |
+328,955
| New | +$19.6M | 0.91% | 11 |
|
Other funds holding DGX
VCM
VPM
EIG
Allstate Corporation's DGX Position: Q1 2026 in Review
Allstate Corporation increased its Quest Diagnostics (DGX) stake by 70% in Q1 2026, buying an estimated $1.18M and bringing the position to 14,782 shares worth $2.9M. The position accounts for 0.03% of the portfolio, ranked #379.
Allstate Corporation first reported a position in DGX in Q2 2013 and has held it in 35 quarters since. The position peaked at $27.3M in Q3 2013. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Allstate Corporation held 14,782 shares of Quest Diagnostics worth $2.9M as of Q1 2026.
- Allstate Corporation bought 6,094 Quest Diagnostics shares in Q1 2026, an estimated $1.18M.
- Quest Diagnostics made up 0.03% of Allstate Corporation's portfolio in Q1 2026, its #379 holding.
- Allstate Corporation first reported a position in Quest Diagnostics in Q2 2013 and has held it in 35 quarters since.
- Allstate Corporation's Quest Diagnostics position peaked at $27.3M in Q3 2013.
- 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Allstate Corporation's 13F filing for Q1 2026, filed 11 May 2026.